Ertugliflozin with sitagliptin

PBAC's latest decision on Ertugliflozin with sitagliptin: Recommended with restriction (2018). Considered for Type 2 diabetes mellitus in patients inadequately controlled on dual oral therapy with metformin and a dipeptidyl peptidase 4 inhibitor or sodium-glucose co-transporter 2 inhibitor.

Eligible population

Adults with Type 2 diabetes mellitus with inadequate glycaemic control (HbA1c >7%) on dual oral therapy with metformin and either a DPP4 inhibitor or SGLT2 inhibitor.

Therapy area

Endocrinology

Line of therapy

Any

Evidence base

RCT

Primary endpoint

HbA1c

Pivotal trial size

462 patients

Key trials

P006 (VERTIS SITA2), Mathieu 2015, Softeland 2017, Jabbour 2014, Matthaei 2015, Tinahones 2016

Comparator

dapagliflozin plus saxagliptin plus metformin; empagliflozin plus linagliptin plus metformin

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis conducted; no ICER calculated.

Similar precedents

• Ertugliflozin
  similarity 0.89
• Dapagliflozin with sitagliptin
  similarity 0.83
• Empagliflozin with linagliptin
  similarity 0.82
• Sitagliptin phosphate
  similarity 0.78
• Empagliflozin, empagliflozin with metformin, linagliptin, linagliptin with metformin
  similarity 0.79
• Sitagliptin
  similarity 0.78